Innohep

Tinzaparin sodium, the active ingredient in Innohep, is a low molecular weight heparin presented as a sterile injectable solution for subcutaneous use. It is employed to prevent and treat venous thromboembolic disorders in patients at risk, including deep‑vein thrombosis and pulmonary embolism. GNH USA supplies Innohep as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Innohep, a low molecular weight heparin, is used in the management of venous thromboembolic conditions. - Deep vein thrombosis (DVT) prevention: lowers the incidence of clot formation in at‑risk surgical or immobilised patients. - Acute DVT treatment: facilitates clot resolution and reduces progression of the thrombus. - Pulmonary embolism (PE) prevention and treatment: helps avert embolic events and supports recovery after an episode. - Surgical thromboprophylaxis: provides prophylaxis against thromboembolic complications in patients undergoing major surgery.

Common Side Effects: - Injection site erythema or bruising. - Minor bleeding such as nosebleeds or gum bleeding. - Transient elevation of liver enzymes. - Mild thrombocytopenia. - Gastrointestinal discomfort.

Serious or Rare Side Effects: - Major hemorrhage, including intracranial or gastrointestinal bleeding. - Heparin‑induced thrombocytopenia (HIT) with paradoxical clotting. - Severe allergic reactions or anaphylaxis. - Spontaneous bruising or hematoma formation. - Elevated liver transaminases persisting beyond two weeks.

Before using Innohep, consider the following precautions: - Renal impairment: adjust dose or monitor anti‑Xa levels in patients with reduced kidney function. - History of bleeding: evaluate risk and correct coagulopathies prior to initiation. - Concomitant anticoagulants: avoid simultaneous use with other anticoagulants unless specifically directed. - Pregnancy and lactation: weigh benefits against potential risks; use only if clearly indicated. - Surgery or invasive procedures: discontinue appropriately before the procedure to minimise bleeding. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Innohep may interact with several drug classes. Major Interactions (Avoid): - Concurrent use with other anticoagulants (e.g., warfarin, direct oral anticoagulants) markedly increases bleeding risk. - Systemic thrombolytics: additive anticoagulant effect can lead to severe hemorrhage. - High‑dose aspirin or NSAIDs: potentiate gastrointestinal bleeding.

Moderate Interactions (Monitor Closely): - Antiplatelet agents (e.g., clopidogrel): monitor for signs of bleeding. - Certain antibiotics (e.g., fluoroquinolones) that may affect platelet function. - Drugs affecting renal clearance (e.g., aminoglycosides): adjust monitoring of anti‑Xa activity.